id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-3849-0004,FDA,FDA-2025-P-3849,"Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-04-30T04:00:00Z,2026,4,,,2026-04-30T18:12:42Z,2026-08435,0,0,09000064b92b5df8
FDA-2025-P-3849-0005,FDA,FDA-2025-P-3849,Final Response,Other,Letter(s),2026-04-30T04:00:00Z,2026,4,2026-04-30T04:00:00Z,,2026-04-30T20:25:46Z,,0,0,09000064b92b8854
FDA-2025-P-3849-0003,FDA,FDA-2025-P-3849,Interim Response,Other,Response(s),2026-03-13T04:00:00Z,2026,3,2026-03-13T04:00:00Z,,2026-04-30T18:41:38Z,,0,0,09000064b9214256
FDA-2025-P-3849-0001,FDA,FDA-2025-P-3849,"Citizen Petition from Hyman, Phelps & McNamara, P.C.",Other,Citizen Petition,2025-09-15T04:00:00Z,2025,9,2025-09-15T04:00:00Z,,2025-09-16T00:48:01Z,,1,0,09000064b8f8c824
FDA-2025-P-3849-0002,FDA,FDA-2025-P-3849,"Acknowledgement Letter from FDA DMB to Hyman, Phelps & McNamara, P.C.",Other,Acknowledgement Letter/Receipt,2025-09-15T04:00:00Z,2025,9,2025-09-15T04:00:00Z,,2025-09-16T00:48:05Z,,0,0,09000064b8f8c826